IPO Trending
MANKINDEQ / NSE, BSEListed

Mankind Pharma Limited

Incorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products across a wide range of acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. The company offers over 36 brands such as Manforce, Moxikind-CV, Amlokind-AT, Prega News, and Gudcef, supported by one of the largest distribution networks of medical representatives in India, with over 80% of doctors prescribing its formulations. Ranked 4th in domestic sales in FY2022, Mankind Pharma has received numerous awards, including The Best of Bharat Awards 2022, National Awards for Manufacturing Competitiveness Silver Medal 2021, and recognition for Best Design in Healthcare and performance management excellence.

₹1,026 - ₹1,08015.32x sub
Listed Price1300.00
Listing Gain+20.37%
Review-Analyst Consensus Verdict

May apply

No review summary is available yet.

Apply
00%
May Apply
00%
Neutral
00%
Avoid
00%
Not Rated
00%
No IPO review records are available for this issue yet.
Mankind Pharma Limited IPO Review | GMP, Allotment & Financials | IPO Trending